Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc. is a biopharmaceutical company based in Israel that develops and produces recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx®. The company was founded in 1993 by Dr. Yoseph Shaaltiel and has a manufacturing facility in Carmiel, in Western Galilee.

Protalix's vision is to become a fully integrated biopharmaceutical company that leverages the advantages of its unique technology platform and internal research and development capabilities. The company's pipeline consists of proprietary versions of recombinant proteins that target established pharmaceutical markets and have clinically improved profiles.

One of the company's products is Elelyso®, a treatment for Fabry disease, which was approved by the FDA in 2012 and by other regulatory authorities around the world. Protalix has also collaborated with Chiesi Global Rare Diseases to develop pegunigalsidase alfa, another treatment for Fabry disease, which received a positive opinion from the CHMP in February 2023.

Protalix BioTherapeutics, Inc. has a market cap of $92.5M as of May 2023. The company is listed on the NYSE American and the Tel Aviv Stock Exchange under the ticker symbol PLX. Protalix is committed to delivering innovative therapies and solutions for people affected by rare diseases and other unmet medical needs.

Foundation: 1993
Headquarters: Karmiel, Israel
Website: https://protalix.com/